Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 10/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 10/20 | 0.32 |
| ▸ | TMEM97 | Q5BJF2 | 7/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 2/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | TYR | P14679 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.30 |
| ▸ | FEN1 | P39748 | 1/20 | 0.30 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.30 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.30 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12823100 | 0.88 | DRD4 (0.36) | DRD4SIGMAR1TMEM97HTR6ALOX5AP | |
| SCHEMBL12718756 | 0.87 | GPR119 (0.32) | DRD4SIGMAR1TMEM97GPR119DRD3 | |
| SCHEMBL12823218 | 0.86 | — | — | |
| SCHEMBL12823256 | 0.84 | FFAR1 (0.36) | ALOX5APFEN1 | |
| SCHEMBL12823007 | 0.84 | KDM4E (0.31) | — | |
| SCHEMBL12823219 | 0.84 | KDM4E (0.31) | — | |
| SCHEMBL10303332 | 0.83 | SIGMAR1 (0.32) | DRD4SIGMAR1TMEM97DRD3HTR6 | |
| SCHEMBL12823116 | 0.83 | GRIN2B (0.32) | ALOX5APFEN1 | |
| SCHEMBL12823016 | 0.83 | GPR119 (0.32) | GPR119TYR | |
| SCHEMBL12823003 | 0.83 | NUDT1 (0.33) | SIGMAR1TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, EFHD2 | DRD4 97/4885SIGMAR1 1690/4885TMEM97 2963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.